Table 2.

Mean diurnal IOP (mmHg) of the study eye (ITT population; missing data imputed with Monte Carlo Markov Chain)

Visit statistics		Netarsudil 0.02% QD	Ripasudil 0.4% BID
		N = 122	N = 123
Week 1	LS mean ± SE	16.28 ± 0.143	17.87 ± 0.141
	Difference from ripasudil 0.4% (Netarsudil – ripasudil)	− 1.59
	95% CI	(− 1.98, − 1.20)
	p value	< 0.0001
Week 2	LS mean ± SE	16.02 ± 0.168	17.83 ± 0.166
	Difference from ripasudil 0.4% (Netarsudil − ripasudil)	− 1.81
	95% CI	(− 2.28, − 1.35)
	p value	< 0.0001
Week 4 (Primary endpoint)	LS mean ± SE	15.96 ± 0.157	17.71 ± 0.155
	Difference from ripasudil 0.4% (Netarsudil − ripasudil)	− 1.74
	95% CI	(− 2.17, − 1.31)
	p value	< 0.0001

LS means, SEs, CIs (2-sided), and p values (2-sided) are from ANCOVA model with treatment as a factor and baseline diurnal mean as a covariate; missing data was supplemented by Monte Carlo Markov Chain

BID twice a day, CI confidence interval, IOP intraocular pressure, ITT intent-to-treat, LS least squares mean, N number of patients in the given treatment of ITT population, QD once a day, SE standard error